Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 1a/b Study to Evaluate the Safety & Tolerability of JSP191 in Combination With a Regimen of Low Dose Radiation & Fludarabine in Subjects With MDS or AML Undergoing Hematopoietic Cell Transplantation (HCT)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT04429191
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-28T10:38:08.909137+00:00
Published At
2021-06-11T00:00:00+00:00
Record Updated At
2021-06-11
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["MYELODYSPLASTIC SYNDROME; MDS", "ACUTE MYELOID LEUKEMIA; AML"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2021-06-11"
protocolSection.identificationModule.nctId
"NCT04429191"
protocolSection.identificationModule.officialTitle
"A Phase 1a/b Study to Evaluate the Safety \u0026 Tolerability of JSP191 in Combination With a Regimen of Low Dose Radiation \u0026 Fludarabine in Subjects With MDS or AML Undergoing Hematopoietic Cell Transplantation (HCT)"
protocolSection.statusModule.overallStatus
"UNKNOWN"
protocolSection.designModule.phases
["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • MYELODYSPLASTIC SYNDROME; MDS (protocolSection.conditionsModule.conditions)
  • ACUTE MYELOID LEUKEMIA; AML (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.